Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of intravitreal bevacizumab injections for treatment of
proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after
previous full panretinal photocoagulation (PRP).